# Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

> **NCT01948830** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 650 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Ranibizumab 0.5mg
- **DRUG:** Ranibizumab 0.5mg

## Key facts

- **NCT ID:** NCT01948830
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-17
- **Primary completion:** 2015-11-19
- **Final completion:** 2015-11-19
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948830, "Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01948830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*